By Adam Leitenberger
Originally published by our sister publication, Gastroenterology Endoscopy News
Almost one-third of people followed in an inflammatory bowel disease registry stopped biologic therapy within 1.5 years, most often due to loss of response.
The findings highlight the real-world impact of biologic discontinuation on IBD care and the importance of optimizing therapy to avoid loss of response, according to Edward L. Barnes, MD, MPH, an assistant professor of gastroenterology and